George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc Stephane, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Dec 31;19(1):2167907. doi: 10.1080/21645515.2023.2167907
Carrico J, Hicks KA, Wilson E, Panozzo CA, Ghaswalla P. The annual economic burden of respiratory syncytial virus in adults in the United States. J Infect Dis. 2023 Dec 7. doi: 10.1093/infdis/jiad559
Curran D, Patterson BJ, Van-Oorschot D, Buck PO, Carrico J, Hicks KA, Lee B, Yawn BP. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765-71. doi: 10.1080/21645515.2018.1558689.